No Data
The Recent Pullback Must Have Dismayed Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) Insiders Who Own 58% of the Company
Buchang Pharma Unit Gets Authorization for Vancomycin Hydrochloride Tablets
Buchang Pharmaceuticals Unit's 6% Equity Transferred to New Shareholders
Shandong Buchang Pharmaceuticals Unit Completes Registration Change for License
Shandong Buchang Pharmaceuticals Gets Clinical Trial Approval for Colon Cleansing Tablets
Shandong Buchang Pharmaceuticals (603858.SH): The pharmaceutical company has received the notice of acceptance for clinical trials of compound sodium sulfate tablets.
Shandong Buchang Pharmaceuticals (603858.SH) announced on November 13 that the company recently learned that its wholly-owned subsidiary, Baoding Tianhao Pharmaceutical Co., Ltd., has received the acceptance of the application for registration clinical trials of the pharmaceutical "Compound Sodium Sulfate Tablets" from the National Medical Products Administration and has received the "Acceptance Letter". Compound Sodium Sulfate Tablets are used for colon cleansing before adult colonoscopy.
Shandong Buchang Pharmaceuticals (SHSE:603858) Shareholders Have Endured a 15% Loss From Investing in the Stock Three Years AgoNo Data
No Data
